Could a new pill ease borderline personality disorder symptoms?
NCT ID NCT05356013
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether Caplyta (lumateperone), a drug already used for other mental health conditions, can reduce symptoms of borderline personality disorder (BPD). Sixty adults with BPD received either Caplyta or a placebo pill for 8 weeks. Researchers measured changes in BPD symptom severity using a standard rating scale.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Caplyta (lumateperone), an atypical antipsychotic drug
What this could lead to
If it works, this could point toward a new medication option to ease symptoms of borderline personality disorder.
What could go wrong
This is a small, early-phase (Phase 2) study with only 60 participants. The drug may not prove more effective than placebo, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BORDERLINE PERSONALITY DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Chicago Medical Center
Chicago, Illinois, 60637, United States